New publication : An anti-diabetic drug targets NEET (CISD) proteins through destabilization of their [2Fe-2S] clusters

ENYO is proud to share international collaborative study showing the anti-diabetic potential of the small molecule dEF2905 (M1) designed by ENYO Pharma’s drugdiscovery platform.
The study driven by Pr R. Nechushtai from the Hebrew University of Jerusalem demonstrates the efficacy of M1 in correcting defective blood glucose homeostasis in a diabetic mouse model through [2Fe-2S] cluster destabilization of mitochondrial NEET proteins. This publication also highlights the ENYO Pharma’s drug discovery platform inspired by viruses.

Read more »

Published on 10/05/2022

Swiss NASH Foundation sponsorship

We are pleased to sponsor the Swiss NASH Foundation launched in 2019 by Pr Jean-François Dufour. Its mission is to raise awareness and increase the knowledge about NASH and fatty liver in general. Through funding innovative research projects on NASH diagnostics, treatment and patient management, the foundation is joining the fight against this epidemic disease.

https://swissnashfoundation.org/

Read more »

Published on 11/03/2022

Tech Tour Future22 (EIC ScalingUp Roadshow)

23-25 March 2022
Digital event

Jacky Vonderscher will attend the Tech Tour Future22 event, one of a series of EIC ScalingUp Roadshow events, and give a pitch about ENYO Pharma.

1,000 investors challenged over 1,000 selected tech entrepreneurs in 2021 over multiple sessions to level up their investment and growth. This event will allow us to meet the top only, to collaborate with Europe’s leading tech entrepreneurs and investors on future ambitions.

Read more »

Published on 07/03/2022

4th Annual CKD Drug Development Summit

1-3 March, 2022
Boston, USA

ENYO attended the 4th Chronic Kidney Disease Drug Development Summit, the only industry-led event dedicated to accelerating the frontier of preventative and regenerative therapies to meaningfully target kidney disease and enlighten opportunities for indication expansion into rare renal disorders. We presented a poster entitled “VONAFEXOR induces renal and hepatic improvements in NASH-LIVIFY trial results”.

https://ckd3-summit.com/

Read more »

Published on 01/03/2022

Tech Tour Growth & EIC ScalingUP 2022

28 Feb-4 March 2022
Digital event

Jacky Vonderscher presented ENYO Pharma and gave a pitch in the “Biotech, Pharma, Therapeutics” session in front of strategic investors & partners among the top 50 European deep tech growth companies funded by EIC.

https://techtour.com/events/2022/2/event-tech-tour-growth–eic-scalingup-2022%5B2%5D.html

Read more »

Published on 28/02/2022